3.1.1. Any discussion of the OSD market must consider the underlying drivers: the global pharma and small molecule markets. The overall global pharma market is strong, as reviewed in Section I of this report. According to a survey of market research reports, the average anticipated growth of the overall pharmaceutical market is about 6% (Table 4). Generic APIs comprise a significant portion of this market, and although generics are encountering more cost pressures, the generics market itself is also anticipated to continue growing at about 6% through 2030 (Table 5). Novel APIs drive the OSD market, especially innovation within OSD manufacturing, and this market is also anticipated to grow at about the same rate, if not slightly higher than the pharma or generics markets (Table 6).
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
3.2.1. Within the OSD market, tablets have traditionally been the single largest component (Figure 6) and will remain so for the foreseeable future because they are a convenient, inexpensive, and well-established dosage form. Of the 33 small molecule NDAs filed in 2024, 41% were initially made available in tablets (Figure 7). Of the top 50 best-selling small molecule drugs of 2024 (Figure 3), 61% of them are available only as tablets (Figure 8).
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
3.3.1. Orally disintegrating tablets (ODTs) are gaining in popularity due to the ease-of-use among elderly, pediatric, and psychiatric patients. ODTs have additional advantages in that they can bypass first-pass metabolism, enable rapid onset of action, and have enhanced bioavailability in some cases. ODTs can be manufactured by a number of both simple and advanced methods, including spray-drying, freeze-drying, HME, or direct compression. The critical novel attribute in an ODT is the excipient, and companies are working on novel excipients to increase their ODT portfolios.[31] Where an appropriate excipient for an ODT isn’t available, developers are increasingly relying on minitablets or microtablets. While mini- and microtablets accomplish the same user requirement of easier swallowing because they are only 2–3 mm wide, the tooling required to manufacture them is more fragile and more expensive.[30]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.